Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Free Cash Flow data on record, last reported at -$46.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 17.17% year-over-year to -$46.3 million; the TTM value through Dec 2025 reached -$206.1 million, down 52.86%, while the annual FY2025 figure was -$206.1 million, 52.86% down from the prior year.
  • Free Cash Flow reached -$46.3 million in Q4 2025 per OCUL's latest filing, up from -$56.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.6 million in Q3 2023 and bottomed at -$56.7 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$27.1 million, with a median of -$21.4 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 81.85% in 2023, then tumbled 1255.06% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$16.1 million in 2021, then decreased by 18.33% to -$19.1 million in 2022, then decreased by 16.2% to -$22.2 million in 2023, then tumbled by 77.79% to -$39.5 million in 2024, then fell by 17.17% to -$46.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$46.3 million in Q4 2025, -$56.7 million in Q3 2025, and -$56.5 million in Q2 2025.